MCRB Earnings & Financial Statements
Seres Therapeutics, Inc.
$2.72
-$0.18(-6.21%)
43
Overall
80
Value
9
Tech
42
Quality
Market Cap
$29.13M
Volume
60.37K
52W Range
$2.83 - $29.98
Target Price
$17.00
MCRB earnings and financial statements: Seres Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MCRB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $789.0K | - | $126.33M | $7.13M | $144.93M |
| Cost of revenue | $6.54M | $3.53M | - | - | - |
| Operating income | -$93.97M | -$121.31M | -$195.10M | -$246.49M | -$64.49M |
| EBITDA | $9.83M | -$118.89M | -$180.28M | -$236.80M | -$54.20M |
| Net income | $5.70M | $136.0K | -$113.72M | -$250.16M | -$65.58M |
| EPS (diluted) | $0.64 | - | $-17.80 | $-46.20 | $-14.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $138.19M | $139.81M | $358.60M | $348.78M | $354.86M |
| Total liabilities | $93.97M | $126.03M | $403.46M | $338.00M | $223.35M |
| Shareholders’ equity | $44.22M | $13.78M | -$44.86M | $10.78M | $131.51M |
| Cash and equivalents | $45.77M | $30.79M | $127.97M | $163.03M | $180.00M |
| Long-term debt | $72.58M | $82.97M | $193.20M | $158.53M | $42.60M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.12M | -$148.61M | -$117.35M | -$228.82M | $6.69M |
| Capital expenditure | -$42.0K | -$380.0K | -$7.97M | -$9.82M | -$9.57M |
| Free cash flow | $865.0K | -$148.99M | -$125.33M | -$238.64M | -$2.88M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MCRB | $2.72 | -6.2% | 60.37K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Seres Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW